Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer... Show more
Verastem Oncology is a commercial-stage biopharmaceutical company focused on cancers driven by the RAS/MAPK pathway — a core cellular signaling network that promotes cancer cell growth and survival. The company's near-term franchise is AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor) that received accelerated approval in May 2025 as the first therapy specifically indicated for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
Over the medium term, Verastem's strategic center of gravity is shifting toward VS-7375, an oral, potentially best-in-class KRAS G12D inhibitor. KRAS is one of the most frequently mutated cancer genes, and the G12D variant represents a large, largely unserved addressable market across pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung cancer (NSCLC). Verastem's differentiated thesis rests on a dual ON/OFF binding mechanism, deep responses, and a tolerability profile with comparatively low gastrointestinal and liver toxicity — attributes that could distinguish it from pan-RAS rivals such as Revolution Medicines' daraxonrasib.
The structural challenge is competition and scale. The KRAS field includes Amgen, Bristol Myers Squibb, Incyte, and Revolution Medicines, several of which possess larger balance sheets. Verastem's ability to sustain a first-mover position in KRAS G12D will depend on the pace and quality of its registrational data, not on historical stock performance.
Several discrete events could materially reshape investor sentiment. The most immediate is the initial registrational data for VS-7375 across the three tumor types, which management indicated could arrive around October 2026, alongside the commencement of Phase 3 trials in the second half of 2026. Because these readouts could support an accelerated approval pathway — potentially making VS-7375 among the first approved KRAS G12D inhibitors — they carry outsized weight.
A second catalyst is the FDA decision on the AVMAPKI FAKZYNJA CO-PACK Blister Pack NDA (New Drug Application), expected by February 7, 2027. A separate confirmatory milestone is the RAMP 301 Phase 3 topline readout anticipated around mid-2027, which could validate the broader LGSOC opportunity regardless of KRAS mutation status and support label expansion in Europe and Japan.
Analyst activity has been notably constructive. Jefferies raised its price target to $13 from $11 while keeping a Buy rating, describing VS-7375 as having best-in-class potential. Mizuho maintained its rating and raised its target to $14, while RBC Capital reiterated Outperform and lifted its target to $19, and BTIG has carried an even higher target. The consensus price target sits near $15, well above recent trading levels — though individual firm targets range widely, reflecting genuine uncertainty about trial outcomes.
Verastem's trajectory is sensitive to the broader biotechnology financing cycle. Unprofitable, development-stage companies are disproportionately exposed to interest-rate policy: higher rates raise the cost of capital and compress valuations, while easing conditions tend to improve access to funding and support risk appetite. The company's $136 million cash position, which extends runway into the second half of 2027, provides a buffer but also means future dilution is a live consideration.
Regulatory climate is a second macro driver. Verastem's own filings note uncertainty around U.S. healthcare policy and regulatory actions. Drug-pricing reforms, accelerated-approval scrutiny, and reimbursement changes could affect both the commercial ramp and the path to conversion of accelerated approvals. On the demand side, oncology remains structurally defensive: cancer treatment volumes are less cyclical than consumer spending, and rare-cancer niches such as LGSOC carry limited pricing competition in the near term. Geopolitical and manufacturing risks also warrant attention, given Verastem's reliance on a Chinese partner (GenFleet) for VS-7375 and third-party contract manufacturers.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is built to surface developing trends, evaluate potential breakouts or reversals, and let users explore predictions across a broad universe of tradable instruments. The platform organizes searchable prediction categories, incorporates historical context, and supports alert-oriented functionality to keep users informed of shifting signals. For investors tracking biotechnology names such as Verastem, tools like this can complement fundamental research by adding a quantitative, momentum-aware perspective to the decision-making process.
Looking toward 2026 and beyond, Verastem's long-term narrative hinges on three structural themes. First is market expansion: converting the LGSOC accelerated approval into traditional approval and extending the label into Europe and Japan would enlarge the commercial opportunity for the core franchise. Second is pipeline diversification: successful VS-7375 data across pancreatic, colorectal, and lung cancers would reposition the company from a single-indication commercial player into a multi-franchise oncology platform. Third is cost and margin evolution: as revenue scales against a rising research-and-development budget, the path to profitability depends on disciplined spending and the avoidance of dilutive financing ahead of major data inflections.
Competitive threats remain the key counterweight. The pace of rival KRAS G12D programs, evolving standard-of-care regimens in pancreatic cancer, and potential regulatory delays could all compress the window of differentiation. Analyst expectations, reflected in the rising consensus price target and maintained Buy and Outperform ratings, suggest the Street is pricing in meaningful pipeline optionality — but the dispersion across targets underscores that the 2026–2027 data readouts, rather than any single forecast, will ultimately determine whether that optimism is justified.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with ZYME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then ZYME could also see price increases.
| Ticker / NAME | Correlation To VSTM | 1D Price Change % | ||
|---|---|---|---|---|
| VSTM | 100% | -7.73% | ||
| ZYME - VSTM | 44% Loosely correlated | -2.68% | ||
| SRPT - VSTM | 40% Loosely correlated | -5.93% | ||
| MLYS - VSTM | 40% Loosely correlated | -3.53% | ||
| ARVN - VSTM | 40% Loosely correlated | -4.15% | ||
| TSHA - VSTM | 39% Loosely correlated | -1.33% | ||
More | ||||
a company that discovers and develops drugs
Industry Biotechnology
VSTM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 38 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 71 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
VSTM moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VSTM crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 204 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.596). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.